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School, Boston, Massachusetts
Mechanisms of action of various hormones and vasoactive substances
on glomerular ultrafiltration in the rat. Angiotensin II (All) and arginine
vasopressin are capable of triggering glomerular mesangial cell contrac-
tion in vitro. A similar mechanism acting in vivo to reduce glomerular
capillary surface area could account for the decline in the ultrafiltration
coefficient (Kf) that occurs in single glomeruli in response to infusion of
these substances. Less clear is the mechanism whereby similar declines
in K1 are induced with infusions of dibutyryl cyclic AMP (DBcAMP),
parathyroid hormone (PTH), and prostaglandins, because PTH and
POE2, at least, are incapable of eliciting mesangial cell contraction in
vitro. To further explore the factors that regulate K1 in vivo, we
performed micropuncture experiments in 47 euvolemic Munich-Wistar
rats. Infusions of DBcAMP, PTH, prostaglandins 12 and E2 led to lower
mean values for plasma flow rate (QA) and K1 in superficial glomeruli
than were found in animals given vehicle alone (control group), whereas
averavalues for glomerular transcapillary hydraulic pressure differ-
ence (P) and total renal arteriolar resistance (RTA) tended to be higher.
These increases in P and RTA, and decreases in QA and K1, with
DBcAMP, PTH, P012, and POE2 are typical of changes induced by All.
Indeed, when saralasin, a competitive All antagonist, was infused
together with these various vasoactive substances, the effects on P,
QA, RTA, and K1 were largely abolished. Therefore, the actions of
DBcAMP, PTH, PGI,, and POE2 on the glomerular microcirculation
appear to depend on an intermediate action of All. By contrast,
although pitressin (ADH) infusion also led to a significant decline in K1,
saralasin administration did not reverse this change, suggesting that the
action of ADH on the glomerular microcirculation is independent of a
pathway involving All. Based on these studies, it seems reasonable to
propose that All and ADH are both potentially important regulators of
mesangial cell contraction, and thereby. glomerular capillary filtering
surface area and K1.
Mécanismes de l'action de différentes hormones et substances vaso-
actives sur l'ultraflltration glomérulaire chez le rat. L'angiotensine 11
(All) et l'arginine vasopressine peuvent dëclencher in vitro une con-
traction des cellules mésangiales glomérulaires. Un mCcanisme sembla-
hie qui agirait in viva et réduirait Ia surface du capillaire glomérulaire
pourrait expliquer Ia diminution du coefficient d'ultrafiltration (K1) qui
survient dans les glomerules isolés en rCponse it Ia perfusion de ces
substances. Le mCcanisme par lequel des diminutions semblables de K1
sont déterminees par des perfusions de dibutyryl cAMP (DBcAMP),
d'hormone parathyroidienne (PTH) et de prostaglandines est moms
clair puisqu'au mains PTH et PGE2 sont incapables de déclencher Ia
contraction des cellules mésangiales in vitro. Afin de mieux explorer les
facteurs qui régulent K11n vivo, des experiences de micro-ponctions ont
été réa!isées chez 47 rats Munich-Wistar euvolCmiques. Les perfusions
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de DBcAMP, PTH, prostaglandines 12 et E2 ont entrainé une diminution
du debit plasmatique (QA) et du K1 dans les glomérules superficiels par
rapport aux animaux ne recevant que Ic véhicule (groupe contrble) alors
que les valeurs rnoyennes de Ia difference de pression hydraulique
transcapillaire, AP, et Ia resistance artériolaire totale, RTA, tendaient a
Ctre plus Clevées. Ces augmentations de P et RTA et les diminutions de
QA et K1 avec DBcAMP, PTH, P012 et POE2 sont typiques des
modifications induites par All. En effet, quand Ia saralasine, un
antagoniste compétitif de All, a été perfusee en méme temps que ces
diffCrentes substances vaso-actives, les effets sur P, QA RTA, et K1
ont été en grande partie abolis. Ainsi les actions de DBcAMP, PTH,
P012, et POE2 sur Ia microcirculation glomérulaire paraissent dépendre
d'une action intermédiaire de All. Au contraire, bien que Ia perfusion
d'ADH determine aussi une diminution significative de K, l'adminis-
tration de saralasine n'abolit pas cette modification, cc qui suggCre que
l'action de I'ADH sur Ia microcirculation glomerulaire ne depend pas
d'une voie impliquant l'All. Sur Ia base de ces etudes il semble
raisonnable de proposer que All et ADH soient a Ia fois des rCgulateurs
importants de La contraction des cellules mesangiales et, de cc faiL, de Ia
surface de filtration glomerulaire et de K1.
Although perfusion of capillaries within a single glomerulus in
amphibia is known to be intermittent (that is, moment-to-
moment variation in individual capillary patency and perfusion)
[1—31, a similar process for regulating perfusion and filtration in
glomeruli in mammals has been regarded as unlikely [4].
Recently, however, evidence has been accumulated in the rat
that leads us to believe that a reexamination of this issue is
warranted, Antidiuretic (ADH) and parathyroid (PTH) hor-
mones, prostaglandin E1 (POE1), acetyicholine, angiotensin II
(All), histamine, and dibutyryl cyclic AMP (DBcAMP) are
vasoactive substances shown to be capable of influencing the
process of glomerular ultrafiltration, in large part by reducing
the glomerular capillary ultrafiltration coefficient (Kr) [5—9]. As
shown in Fig. 1, at least four pathways could be involved in the
regulation of glomerular perfusion and filtration by these vaso-
active compounds. Pathway I involves the direct stimulation of
contraction of glomerular mesangial cells, the effect of which is
to reduce glomerular capillary patency and hence K. Two
substances, arginine vasopressin (AVP) and All are known to
stimulate mesangial cell contraction in vitro [10]. In vivo, the
effect of All on K in the rat is reversed by verapamil and
manganese ion [11], known blockers of smooth muscle contrac-
tion, and by the All antagonist saralasin [121. Although no
competitive antagonist of AVP action on K has yet been
studied in vivo, there is indirect evidence to suggest that Kf
varies inversely with circulating AVP levels [5].
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Fig. 1. Diagram of possible pathways for regulation qf glomerular
pemfusion and filtration h' the vasoactive compounds dihutvryl cyclic
AMP (DBcAMP), PTH, PG!,, PGE, aceivicholine (Ach), histamine
(HIS), arginine vasopressin (AVP), and angiotensin II (All). K1 is the
glomerular capillary ultrafiltration coefficient.
Less clear is the mechanism by which DBcAMP, PTH,
prostaglandins, acetylcholine and histamine also elicit changes
in K1. Pathway 2 (Fig. 1), involving a direct effect of these
substances on mesangial cell contraction seems unlikely, at
least for prostaglandin E2 and PTH, for Ausiello et a! [101 were
unable to trigger mesangial cell contraction by these substances
in vitro. Of note, however, all of the substances shown in the
top left-hand panel of Fig. I are known to enhance cyclic
nucleotide generation in isolated glomeruli [13—15], and cAMP
has been shown to be a potent stimulus for renal renin release
[16—19]. The possibility exists, therefore, as shown in pathway
3, that these vasoactive substances modulate K1 by virtue of
their ability to promote local intrarenal All formation, with the
latter serving as the direct mediator of mesangial cell contrac-
tion and eventual decline in K1. Finally, the possibility also
exists that PTH, prostaglandins, and other substances shown in
the top left-hand panel of Fig. I initiate changes in K1 by some
pathway independent of the mesangial cell, as in pathway 4. It
seemed to us that saralasin might be a useful agent to help
distinguish which of these last three pathways is primarily
involved. Were this All antagonist to reverse the fall in K1
induced by these vasoactive drugs, pathways 2 and 4 would be
viewed as unlikely and pathway 3 would be favored. According-
ly, we undertook the present study to evaluate whether All
serves as the mediator of the K1-lowering effects of DBcAMP,
PTH, ADH, PGI2 and POE2 in euvolemic Munich-Wistar rats.
Methods
Micropuncture studies were performed on 47 adult Munich-
Wistar rats, each weighing between 215 to 320 g. Each rat was
allowed free access to water and a standard rat pellet diet until
the morning of study. Immediately after anesthesia was induced
with mactin (100 mg/kg, i.p.). the left femoral artery was
catheterized, and approximately 70 il of arterial blood was
collected for baseline hematocrit determination. This arterial
catheter was used for subsequent periodic blood sampling and
estimation of mean femoral arterial pressure (A). AP was
monitored with art electronic transducer (model P23Db.
Statham Instruments Div., Gould Inc., Hato Rey, Puerto Rico)
connected to a direct-writing recorder (model 7712, Hewlett-
Packard Co., Waltham, Massachusetts). Polyethylene catheters
were also inserted into the right and left jugular veins for
infusion of inulin, prostaglandin synthetase inhibitor, saralasin,
and isoncotic rat serum. An i.v. infusion of 7.59/ inulin solution
in 0.9% sodium chloride then was started at a rate of 1.2 mu
hour. Solutions containing either DBcAMP (83 p,g/kg/min, i. v.).
PTH (5 U/kg/mi i.v.), Pitressin (0.6 mU/kg/mm, i.v.), PG!, (62
ng/kg/min, i.a.) PGE2 (125 ng/kg/min, ia.). or vehicle alone
(Tris buffer or saline) were infused by the protocol shown in
Fig. 2.' The intra-aortic (i.a.) infusions of PGI2 (or its vehicle
alone, Tris buffer, pH 8.5, 300 mOsm/liter) and POE2 were
administered at the rate of 3 uI/mm via a 27-gauge needle placed
into the abdominal aorta just above the origin of the left renal
artery. To suppress the possibility of tissue prostaglandin
release in response to these various substances, we also infused
a prostaglandin synthetase inhibitor (indomethaci n or meclofen-
amate, 2 mg/kg/h, iv.) starting 45 mm before and continued
throughout the duration of each experiment (Fig. 2).
Following tracheostomy, rats were prepared in routine fash-
ion for micropuncture study, as described previously [20]. After
an initial equilibration period of 45 mm, appropriate measure-
ments and collections needed to characterize glomerular
dynamics and K1 were obtained in the initial study period (see
below). Then while infusion of the test vasoactive substance
was continued, an infusion of the All antagonist saralasin (5 p.g/
kg/mm, i.v.), was begun in each rat, and after a second
equilibration period of 30 mm, all measurements and collections
were repeated in each rat (Fig. 2).
Throughout the period of surgical preparation and experi-
mental study, all rats received a continuous i.v. infusion of
isoncotic rat serum to maintain circulating plasma volume at
conscious (or euvolemic) levels. Because plasma volume of rats
prepared for micropuncture is reduced by approximately 20%
relative to the conscious animal [211, the following protocol for
maintaining the euvolemic state was used. Soon after collection
'The dosage of DBcAMP used in the present study was selected to
represent the maximal (lose unassociated with a vasodepressor effect in
the presence of prostaglandin synthetase inhibition. The dosages of
PTH and Pitressin used in the present study, similarly selected to avoid
systemic vasodilation and vasoconstriction, respectively, were the
same as those used in this laboratory previously [5. 6]. For PGl and
PGE2, systemic vasodepressor effects in the absence of prostaglandin
synthetase inhibition were elicited at dosages in excess of I .0 .g/kg/min
and 2.0 ig/kg/min, respectively. When prostaglandin synthetase inhibi-
tors and saralasin were infused beginning 45 mm prior to and during the
dose-response trials, the systemic vasodepressor tendency for POL and
PGE2 was enhanced. Dosages of 62 ng/kg/min for PGI2 and 125 ng/kg/
mm for PGE2 proved to be the maximal amounts that were unassociated
with systemic hypotension; therefore, these dosages were used in the
present study.
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of the baseline arterial blood sample, isoncotic rat serum was
infused for 45 mm at the rate of 7 to 10 mIlk glhr, followed by
reduction in infusion rate to 1.5 mI/kg/hr for the remainder of
each experiment to maintain the hematocrit value at the base-
line level measured immediately after induction of anesthesia.
This protocol was found by us to be successful in maintaining
plasma volume at the level that existed prior to induction of
anesthesia [22].
Micropuncture studies: Pre-saralasin period, in all experi-
ments, initial micropuncture measurements were performed as
follows. Exactly timed (1 to 3 mm) samples of fluid were
collected from surface proximal convolutions of at least three
nephrons for determination of flow rate and inulin concentra-
tion and calculation of single nephron glomerular filtration rate
(SNGFR). Coincident with these tubule fluid collections, two or
three samples of femoral arterial blood were obtained in each
period for determination of systemic arterial hematocrit (Hct),
total protein and inulin concentrations in plasma. In addition,
two or three samples of urine from the experimental (left)
kidney were collected for determination of flow rate, inulin
concentration and calculation of whole kidney glomerular filtra-
tion rate (GFR). For these urine collections, an indwelling
ureteral polyethylene catheter (PE-lO) was inserted into the left
ureter.
Time-averaged pressures were measured in surface glomeru-
lar capillaries (PGC), proximal tubules (PT), efferent arterioles
(PE) and third-order peritubular capillaries (Pc) with a continu-
ous-recording, servo-null micropipette transducer, using pi-
pettes with outer tip diameters of 2 to 4 m and containing 2.0 M
sodium chloride. Hydraulic output from the servo-null system
was coupled electronically to a second channel of the Hewlett-
Packard recorder by means of a pressure transducer. To
estimate the colloid osmotic pressure of plasma entering and
leaving glomerular capillaries, we also measured protein con-
centrations (C) in femoral arterial (CA) and surface efferent
arteriolar (CE) blood plasma samples. Colloid osmotic pressure
(H) was calculated according to the equation of Deen, Robert-
son, and Brenner [23]. Values for CA, and thus "A. for femoral
arterial plasma are taken as representative of values of C and [I
for the afferent end of the glomerular capillary network. These
estimates or pre- and postglomerular plasma protein concentra-
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Fig. 2. Protocol for infusions.
tions permit calculation of single nephron filtration fraction
(SNFF) and initial glomerular capillary plasma flow rate (QA),
using the equations given below.
(2) Saralasin period. Upon completion of the initial measure-
ments, all rats in each group were given a continuous i.v.
infusion of saralasin acetate (sar'-aIa8-AII, Eaton Laboratory,
Div. of Morton Norwich Products, Inc., Norwich, New York)
at the rate of 5.0 p.g/kg/min (1.2 ml/hr). After a 30-mm equilibra-
tion period, all of the measurements and collections described
above were repeated.
Analytical methods. The volume of fluid collected from
individual proximal tubules was estimated from the length of
the fluid column in a constant-bore capillary tube of known
internal diameter. The concentration of inulin in tubule fluid
was measured, usually in duplicate, by the microfluorescence
method of Vurek and Pegram [24]. Inulin concentrations in
plasma and urine were determined by the macroanthrone
method of FUhr, Kaczmarczyk, and Kruttgen [25]. Protein
concentrations in efferent arteriolar and femoral arterial blood
plasmas were determined, usually in duplicate, using the fluoro-
metric method of Viets et a! [26].
Calculations. Single nephron glomerular filtration rate was
calculated by
SNGFR = (TF/P)1 VTF (1)
where (TF/P)1 and VTF refer to transtubular inulin concentra-
tion ratio and tubule fluid flow rate, respectively.
Single nephron filtration fraction was by
SNFF=1— (2)
where CA and CE denote afferent and efferent arteriolar protein
concentrations, respectively.
Initial glomerular plasma flow rate was by
SNGFR
QA = SNFF (3)
Blood flow rate per single afferent arteriole or glomerulus was
GBF = (4)
— HctA
where HCtA, the hematocrit of afferent arteriolar blood, is taken
to be equal to femoral arterial hematocrit.
Efferent arteriolar blood flow rate was
EABF = GBF — SNGFR (5)
Resistance per single afferent arteriole was
RA = AP—PGc x(7.962 x lOla) (6)
where the factor 7.962 x 1010 is used to give resistance in dyn
sec cm5 when AP and PC are expressed in millimeters of Hg
and GBF in nanoliters per minute.
Resistance per single efferent arteriole was
RF = GC C x (7.962 x 1010) (7)EABF
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Total arteriolar resistance for a single pre- to post-glomerulair
vascular unit was
RTA = RA + RE
Mean glomerular transcapillary hydraulic pressure difference
was
=
— PT
The ultrafiltration coefficient (Kf) is calculated with a differ-
ential equation that gives the rate of change of protein concen-
tration with distance along an idealized glomerular capillary.
This equation, together with its derivation and the method for
its solution, is given in detail elsewhere [23].
Statistical analyses were performed by the Student's paired
and unpaired t test, where appropriate. Statistical significance
is defined as P < 0.05.
Results
Control and dibutyryl cAMP groups: (1) Pre-saralasin pen-
od. Mean values obtained in rats given vehicle alone (Control
Group) and DBcAMP are summarized in Table 1,2 Both groups
were similar in mean values for body and kidney weight and
AP. Mean values for GFR and SNGFR in DBcAMP-treated
animals were significantly lower than they were in the control
group, averaging 0.84 0.07 (sEM) vs. 1.13 0.08 mI/min/
kidney (P < 0.025) and 30.2 2.5 vs. 39.5 1.9 nl/min (P <
0.01), respectively. Because the mean value for QA fell (84 7
vs. 119 6 nI/mm, P < 0.05) in proportion to SNGFR during
DBcAMP infusion, mean SNFF values were similar between
groups (Table I). Values for P in the DBcAMP Group
averaged 53 1 mm Hg, a value significantly higher (P < 0.01)
than in the control group, 49 1 mm Hg. Because values for T
were, on the average, the same for both groups (Table 1),
DBcAMP led to a small but significantly higher mean value for
P (40 1 vs. 37 1 mm Hg, P < 0.05). Mean values for E
and Pc were similar in both groups. Although mean values for
RA were also similar in these two groups (Table 1), mean values
for RE (3.0 0.3 vs. 1,8 0.1 >< l0'° dyn sec cm, P <
0.001), and thus RTA (5.8 0.5 vs. 3.9 0.1 x lOb dyn sec
cm5, P < 0.01) were significantly higher in the DBcAMP
group.
Mean values for CA and CE and thus 11Aand 11E were similar
in DBcAMP and control groups. For both groups, average
values for HE/LW were significantly less than unity (Table I).
indicating that these animals were at filtration pressure disequi-
librium.3 Therefore, it was possible to calculate unique values
2Because the results obtained in 2 rats given isotonic saline (the
vehicle for DBcAMP, PTH, ADH, and POE2) and in 5 rats given the
vehicle for P012 (Tris buffer) were essentially indistinguishable for all
quantities measured, results from these 7 rats were pooled in calculating
mean values for the control group. In addition, about 60% of rats in
each group received indomethacin as the prostaglandin synthetase
inhibitor, whereas the remainder received meclofenamate. Once again,
because values obtained with these inhibitors were similar, the results
shown in Table 1 represent pooled averages.
—
3Filtration pressure disequilibrium is defined as iiE/zP < 0.95. In the
pre-saralasin period, this condition obtained in 4 of 7 rats in the control
group, 6 of 8 rats in the DBcAMP group, 5 of 7 rats in the PTH group, 6
of 7 rats in the ADH group, 7 of 8 rats in the PG!2 group and 9 of 10 rats
in the POE2 group. In the saralasin period. lIE/LW ratios of <0.95
obtained in 4 of 7 rats in the control group, 6 of 8 rats in the DBcAMP
(9)
for Kf in each group [23]. As shown in Table I, the mean Kf
value was significantly lower in the DBcAMP group than in the
8 control group (0.035 0.002 vs. 0.081 0.010 nl/[sec ' mm Hg],
(2) Saralasin period. As shown in Table I, infusion of the All
antagonist saralasin did not significantly alter AP in either
group. A marked response to saralasin occurred in the
DBcAMP group, however, in that GFR, SNGFR, and QA rose,
on average by at least 50% whereas average values for these
and all other indices tested in the control group remained
statistically unchanged (Table I). The proportionately greater
increase in QA than in SNGFR in the DBcAMP group in
response to saralasin led to a decline in the mean value of SNFF
from 0.36 0.01 to 0.31 0.01 (P < 0.05). Due to a decrease in
the average value of Pc, (P < 0.025) with saralasin in the
DBcAMP group, LW decreased on average by --12% from its
initial mean value (P < 0.025) because P1 remained unchanged.
Mean values for both PE and Pc rose slightly when saralasin
was added to DBcAMP-treated animals (P < 0.01), as shown in
Table 1. Whereas mean values for CA were similar between
initial and second study periods in both groups, the mean value
for CE (7.8 0.1 vs. 8.4 0.1 g/dl, P < 0.05) declined during
saralasin infusion only in DBcAMP-treated rats. Although RA
changed little in response to saralasin in both groups, RE
declined markedly in the DBcAMP group, on average by —65%
(P < 0.001), leading to a lower mean value for RTA during
saralasin infusion in this group (P < 0.025).
As shown in Table 1, mean values for HE/LW were unaffected
by saralasin infusion in either group, indicating persistence of
filtration pressure disequilibrium. Nevertheless, in response to
saralasin, the average value for Kf in the DBcAMP group
increased markedly, to a value indistinguishable from that in the
control group (Table 1 and Fig. 3). Thus, in response to
saralasin, values for SNGFR, QA and Kf increased in
DBcAMP-treated rats, whereas LW and RTA decreased.
PTH group. (1) Pre-saralasin period. Values obtained in
PTH-treated animals are summarized in Table I. On average,
mean values for body and kidney weights in this group were
similar to those in the control group, as were values for A,
GFR, SNGFR, QA, and SNFF. Values for PGC in the PTH
group averaged 53 1 mm Hg, a value significantly higher (P <
0.01) than in the control group (Table I). As values for PT were,
on average, similar in both groups, PTH led to a slightly but
significantly higher average value for LW (40 I vs. 37 I mm
Hg, P < 0.05). PE and P, on average, were similar in both
groups (Table 1). Whereas mean values for RA were similar in
these two groups, mean values for RE (2.4 0.2 vs. 1.8 0,1 x
1010 dyn sec cm5, P < 0.005) and RTA (5.1 0.4 vs. 3.9
0.1 x lO'° dyn ' sec cm5 P < 0.01) were significantly higher in
the PTH group. Mean values for CA, C, nA, and HE were
similar in PTH and control groups (Table I). For both groups,
average values for flE/LW were significantly less than unity.
group, 4 of 7 rats in the PTH group, 6 of 7 rats in the ADH group, 6 of 8
rats in the PG!2 group, and 7 of 10 rats in the POE2 group. Under these
conditions of filtration pressure disequilibrium, unique values for Kf
could be calculated, in arriving at mean values for K1 for a given study
period in each group, minimum values for K1 (from rats at filtration
pressure equilibrium) were pooled with unique values calculated under
disequilibrium conditiorts.
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PTH infusion resulted in a significantly lower mean value for K
than was found in the control group.
(2) Saralasin period. As shown in Table 1, mean values for
GFR, SNGFR, and QA rose slightly in PTH-treated rats given
saralasin, although these changes were not statistically signifi-
cant. Mean values for AP, P, P, CA, CE, and renal arteriolar
resistances RA, RE, and RTA tended to decline slightly, but
again these changes were not significant. Mean values for
SNFF, PT, E, and Pc were largely unaffected by saralasin. As
shown in Table 1 and Fig. 3, the mean value for K returned
essentially to the level found in the control group during
saralasin infusion, the change relative to the initial PTH study
period being highly significant (P < 0.01).
AD!-! group: (1) Pre-saralasin period. Data for ADH-treated
animals are also summarized in Table 1. Both ADH and control
groups were similar in average body and kidney weights and
mean values for AP, GFR, SNGFR, QA, and SNFF. Values for
P0c averaged 50 1 mm Hg in the ADH-treated rats, a value
similar to that in the control group, 49 1 mm Hg. Values for
PT were significantly lower in the ADH group than in the
control group (8 I vs. 12 Hg, P < 0.05), accounting
largely for the higher average zP value in the ADH group (42
1 vs. 37 1 mm Hg, P < 0,05). As reported previously [5], this
lower P value for the ADH group is believed to be due to the
pronounced antidiuresis induced by exogenous ADH, one
consequence of which is the fall in intratubular hydraulic
pressure everywhere along the nephron. PE and P were
similar, on average, in both groups. As shown in Table 1, ADH
infusion did not alter renal arteriolar resistances, RA and RE.
Also, mean value for HE'P were, on average, significantly less
than unity in ADH-treated rats (Table I), indicating that these
animals were at filtration pressure disequilibrium.3 Therefore,
unique values for K averaged 0.046 0.006 nh/(sec mm Hg),
significantly lower than that for control animals (P < 0.01). In
short, the action of ADH on the glomerulus is confined solely to
the effect on Kf.
(2) Sara/as/n period. As shown in Table I, saralasin failed to
alter AP, GFR, SNGFR, or QA in ADH-treated rats. Values for
PGC, Pi-, and A.P were likewise little changed from the initial
study period. Mean values for CA and CE tended to be slightly
lower during saralasin infusion whereas renal arteriolar resis-
tances RA, RE, and RTA were statistically unchanged. Values
for IIE/ were unaffected, on average, by saralasin in the ADH
group.3 Despite the presence of the All antagonist, the mean K
value remained essentially unchanged at a level significantly
below that found in the control group (Fig. 3).
PG!2 group. (1) Pre-saralasin period. Mean values obtained
in PGI2-treated animals are summarized in Table I. Average
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Table 1. Summary of whole kidney and single nephron function in rats given various vasoactive substances before and during saralasin
infusion"
Before
or during
saralasin
Before
During
Body wt Kidney wt
g g
AP
mm
Hg
Before
During
'30C P1
mm Hg
Ph Pc
CA
g/dl
Before
During
5.8
5.6
5.4
5.4
5.6
5.3
1.22
1.180.l0
49
48
53
45h
53'-
SI
50
51
54
45hd
53'-
46
Before
During
Before
During
260 1.01 110 0.92"
14
108 l26
268 1.09 108 1.04
103 l.2lh
40.4
--l2
39.1 126 0.30
PG!2 group (N = 8 rats)
30.3'- 82'- 0.38"
50.0hd 178"" 0.295d
-9
PGE2 group (N — 10 rats)
35.2 96 0.37
40.7 138" 0.31"
12 42'- 14
-1 --I
12 34h.d lI
12 41" 13
-'-I
12 345 20"
-'-1
Values are expressed as means I SEM. See text for abbreviations.
Calculated from paired data; pre-saralasin vs. saralasin period, P < 0.05.
Calculated from unpaired data; pre-saralasin period for each vasoactive drug vs. pre-saralasin period in control group, P < 0.05.
Calculated from unpaired data; saralasin period for each vasoactive drug vs. saralasin period in control group, P < 0.05.
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Table 1. (Continued)
RA R1 RIA
K
C0 mm hr mm nl/(sec
gidi Hg Hg >< 1010 dyn sec cm mm Hg)
Control group (N = 7 rats)
8.6 19.1 35.5 0.93 2.1 1.8 3.9 0.08!
±0.2 ±0.7
8.6 18.3 35.6 0.92 2.1 1.8 4.0 0.080O2 0.7 l.6 ±0.04 0.l ±0.! ÷0.2 0.0l1
DBCAMP group (N 8 rots)
8.4 17.4 34.4 0.85 2.8 3.0k 5.8k 0.035w
±0.1 ±0.3 ÷0.8 ±0.02 ±0.4 -0.3 ±0.5 ÷0.002
7.80,d 17.6 30.7' 0.89 1.9 l.l01 0.0870
±0.1 ±0.4 ÷0.8 ±0.02 ±0.3 ±0.! ±0.2 ±0.008
PTH group (N = 7 Fats)
8.9 18.3 38.0 0.88 2.5 2.4c 5. ! 0.047c
±0.4 ±0.8 ÷2.7 ±0.02 ±0.2 ±0.2 0.4 ±0.004
8.6 17.0 35.5 0.90 2.2 1.9 4.1 0.0760O3 ±0.7 2.2 ±0.04 ±0.2 ±0.1 0.3 ±0.005
ADJI group (N = 7 mats)
8.2 19.7 32.9 0.84 2.3 1.7 4.0 0.046w
±0.2 O7 I.4 ÷0.03 ÷0.2 ±0.2 0.3 --0.006
7.8 17.4 29.2 0.74 2.5 1.8 4.3 0.038d
±0.2 ±0.4 ± 1.3 ±0.03 0.3 ±0.3 0.4 0.005
PGI- group (N — 8 rats)
9.!" 18.4 39.!" 0.89 2.5 2.9" 5.4" 0.039"
÷0.2 ±0.3 ÷1.3 ±0.02 ±t).2 ±0.2 ÷0.4 ±0.006
770.d 17.4 29.50 d 0.87 l.7 0.901 2.511 0.0880
±0.2 -5-04 --1.0 ÷0.04 0.2 ±0.! ÷0.2 0.006
PGE-, group (N 10 rats)
8.4 7.5 34.3 0.82 2.2 2.5 4.7" 0.032"
±0.2 ±0.4 l.O ±0.03 0.2 ÷0.1 --t1.2 ±t).003
7•5h.i 16.5 28.50.d t).87 1.9 1.40 3.4' 0.0730
±0.2 ±0.6 ±0.5 ±0.03 0.2 ±0.! ±0.3 ±0.006
values for body and kidney weights and AP were similar to sure disequilibrium. Unique values for Kf averaged 0.039 ±
those obtained in the control group. P01, infusion led to 0.006 nl/(sec mm Hg) in this group, a value significantly lower
significantly lower mean GFR and SNGFR values than in the than in the control group (P < 0.005).
control group, averaging 0.92 ± 0.07 vs. 1.13 ± 0.08 mI/mm (P (2) Saralasin period. As shown in Table 1, infusion of
< 0.05) and 30.3 ± 1.5 vs. 39.5 ± 1.9 nI/mm (P < 0.00!), saralasin did not alter AP in rats given P012 but led to
respectively. Due to a larger average decline in QA (82 ± 5 vs. impressive and highly significant increases in GFR, SNGFR,
119 ± 6 nI/mm, P < 0.001) than in SNGFR with P012, SNFF and QA (Table 1). Indeed, values for these indices following
rose significantly (0.38 ± 0.01 vs. 0.32 ± 0.02,P < 0.05) when saralasin were signiFcantly higher than in the saralasin study
compared with the control group. Values for PGC in the POT2 period in the control group. The proportionately greater in-
group averaged 54 ± 1 mm Hg, a value significantly higher (P < crease in QA than in SNGFR with saralasin in P01,-treated rats
0.001) than in the control group, 49 ± 1 mm Hg. Because values led to a significant decline in SNFF, on average from 0.38 ±
for PT were, on average, the same for both groups (Table 1), 0.01 to 0.29 ± 0.01 (P < 0.025). Due to a mean decrease in P0,
P012 was associated with a significantly higher mean value for P declined on average by — 20% from its initial mean value (P
P (42 ± I vs. 37 ± 1 mm Hg, P < 0.001). Mean values for PE <0.05). Average values for P and P rose significantly (P <
and P were similar in both groups. Whereas mean values for 0.05) during saralasin infusion, as shown in Table 1, whereas
RA were also similar for these two groups, mean values for RE RA, RE and RTAdeclined significantly during saralasin infusion,(2.9 ± 0.2 vs. 1.8 ± 0.1 x lO'°dyn sec cm5, P < 0.005) and to levels below those obtained in saralasin treated control rats.
RTA (5.4 ± 0.4 vs. 3.9 ± 0.1 x 10'°dyn sec cm5, P < 0.05) As shown in Table 1, the average value for HE/AP in P012-
were significantly higher in the P012 group. treated rats was unaffected by saralasin infusion. Calculated
Mean values for CA and 11A were also similar in these two unique Kf values in the PG!2 group increased significantly with
groups, whereas values for CE (9.1 ± 0.2 vs. 8.6 ± 0.2 g/dl, P < saralasin, on average to 0.088 ± 0.006 nl/(sec mm Hg), a value
0.05) and 11E (39.1 ± 1.3 vs. 35.5 ± 1.5 mm Hg, P < 0.05) were similar to that observed in control animals (Fig. 3).
significantly higher during PG!2 infusion than in the control PGE2 group: (1) Pre-saralasin period. Mean values obtained
group. The mean value for HE/AP was significantly less than in PGE2-treated animals are summarized in Table I. On aver-
unity during P012 infusion (Table 1), indicating filtration pres- age, values for body and kidney weights in this group were
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similar to those in the control group, as were average values for
AP. Mean values for GFR, SNGFR and QA were slightly but
not significantly lower in the PGE2 group when compared with
the control group, and SNFF values were similar (Table 1).
Values for GC in the PGE2 group averaged 53 1 mm Hg, a
value significantly higher (P < 0.005) than in the control group,
49 1 mm Hg. Because values for PT were, on average, similar
for both groups (Table 1), PGE2 was associated with a signifi-
cantly higher average value for AP (41 1 vs. 37 1 mm Hg, P
< 0.025). PE and Pc, on average, were similar for these two
groups, as were mean values for RA. But, mean values for RE
(2.5 0.1 vs. 1,8 0.1 x 10'°dyn sec cm5, P <0.005) and
RTA (4.7 0,2 vs. 3.9 0.1 )< 10'°dyn sec cm5, P < 0.05)
were significantly higher in the PGE2 group.
Mean values for CA, CE, "A' and 11E were similar for PGE2
and control groups. Filtration pressure disequilibrium obtained
during PGE2 infusion and unique values for K averaged 0.032
0.003 nl/(sec mm Hg), a value significantly lower than in
control animals (P < 0.025).
(2) Saralasin period. As shown in Table 1, infusion of
saralasin essentially reversed the effects of PGE2 on the renal
cortical microcirculation. Whereas mean values for GFR,
SNGFR and QA rose, on average by 16% (P < 0.05), 10%
(P>0.10) and 45% (P < 0.005), mean values for AP, RE, and
RTA declined significantly. Due to a greater average increase in
QA than in SNGFR, saralasin led to a significant decline in
SNFF in PGE2-treated rats, on average from 0.37 0.02 to 0.31
0.02 (P < 0.05). Values for CA and 11A were largely
unaffected by saralasin, but CE (7.5 0.2 vs. 8.4 0.2, P <
0.05) and 11E (28.5 0.5 vs. 34.3 1.0, P < 0.05) declined
significantly in this second study period. PE and Pc rose from 13
Ito 20 I mmHg(P<0.0l)andfrom7 Ito 12 1mm Fig
(P < 0.01) respectively, reaching values even higher than in the
control group (P < 0.01) (Table 1). As with PGI2, the Kf-
lowering effect of PGE2 was largely reversed by saralasin, as
shown in Fig. 3,3
Discussion
The purpose of the present study was to examine the mecha-
nism(s) by which DBcAMP, PTH, ADH, P012, and PGE2 elicit
changes in the glomerular capillary ultrafiltration coefficient,
K, and the other determinants of SNGFR in the Munich-Wistar
rat. During DBcAMP infusion, despite no significant change in
AP, an increase in AP was observed. SNGFR and QA declined
by — 25% and - 30%, respectively, the latter due to impressive
increases in RE and RTA. These effects are identical to those
previously described for DBcAMP [5], as was the finding
shown in Table 1 and Fig. 3 that DBcAMP infusion leads to a
marked decline in K. These increases in AP, RE, and RTA, and
decreases in QA and K, are typical of changes seen when
exogenous All is infused [8, II, 27] or when endogenous All
levels are augmented, as during chronic salt deprivation [281.
We therefore studied the effects of saralasin infusion, a compet-
itive antagonist of All, on the glomerular actions of DBcAMP.
In the presence of saralasin, the effects of DBcAMP on AP, QA'
RE, TRA, and K1 were effectively reversed (Table I and Fig. 3).
Thus, in the Munich-Wistar rat, the action of DBcAMP on the
glomerular microcirculation appears to involve an intermediate
effect of All. In the control group, however, no significant
effects of prostaglandin inhibition alone or in combination with
saralasin were found, suggesting that, in the absence of
DBcAMP infusion (or the other vasoactive substances exam-
ined in this study), endogenous All plays little role in regulating
glomerular dynamics under euvolemic conditions. An identical
conclusion for the kidney as a whole has also been reported
[29].
The effects of PTH infusion on AP were also negligible,
whereas AP rose slightly but significantly (Table I). Due to the
PTH-induced reductions in K and QA. SNGFR decreased
slightly but not significantly. Because a reduction in QA with
comparable doses of PTH was not seen by us previously in non-
indomethacin-treated rats [61, the likelihood exists that PTH
exerts a mild vasoconstrictor action on the renal cortical
microcirculation that only becomes evident when endogenous
prostaglandin synthesis is suppressed, as was the case in the
present study. During saralasin infusion, the effects of PTH on
SNGFR, QA, AP, and Kf were again largely reversed, suggest-
ing that, as with DBcAMP, the action of PTH on the glomerular
microcirculation of the Munich-Wistar rat requires the action of
All.
Administration of a nonpressor dose of Pitressin, a vasoac-
tive peptide known to exert similar effects on the glomerular
microcirculation to that of the native rat antidiuretic hormone,
arginine vasopressin [5], failed to alter values for SNGFR or
total kidney GFR significantly (Table 1). Nevertheless, a uni-
form fall in PT was observed, unaccompanied by a correspond-
ing change in PGC, so that AP increased in each rat. This fall in
P1 reflects the pronounced antidiuresis induced by exogenous
ADH [5]. Given near-constancy of CA and QA, the relative
4A possible alternative choice for inhibiting the putative action of All
in mediating mesangial cell contraction might be a converting enzyme
inhibitor (for example. SQ 20881 or Captopril). Insofar as converting
enzyme inhibitors lead to accumulation of bradykinin, a potent K-
lowering substance in vivo [7], and because renal cortical converting
enzyme has been shown not to be affected by converting enzyme
inhibitors (46), we saw little merit for their use in the present study.
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Hormonal influences on GFR 449
constancy of SNGFR in rats given Pitressin could only have
been the consequence of a significant reduction in Kf, the effect
of which served to offset the rise in AP and prevent the increase
in SNGFR that would otherwise have been expected to occur.
Unlike the findings with DBcAMP and PTH, the administration
of saralasin did not reverse any of the effects on the determi-
nants of glomerular ultrafiltration induced by Pitressin. There-
fore, the findings in the present study suggest that the mecha-
nism of the ADH-associated fall in Kf is independent of a
pathway involving A!!. This conclusion is further supported by
the finding that ADH failed to alter RA or RE and that saralasin
infusion into ADH-treated rats also failed to alter RA or RE.
Thus, the present findings suggest that ADH acts selectively on
Kf (presumably via mesangial cell contraction). All not only
elicits this same effect on mesangial contraction but stimulates
efferent arteriolar contraction as well.
The effects of PG!2 on glomerular dynamics were qualitative-
ly similar to those of DBcAMP and PTH in that AP, RE, and
RTA increased whereas SNGFR, QA. and K1 fell significantly
(Table 1). Our findings regarding the decrease in QA with PGI2
are similar to those reported by Baer and McGiff [30] and
Gerber and Nies [31], who observed significant decreases in
renal blood flow during PGI, infusion in the rat. During
combined saralasin and PG!2 infusion, however, the strikirtg
vasoconstrictor effects of PG!2 on the renal cortical microcircu-
lation were largely abolished, as was the decline in Kf. Indeed,
in the presence of saralasin, the action of PGI2 was transformed
from that of a potent vasoconstrictor (low QA and high RTA) to
an equally potent vasodilator (high QA and low RTA).
——
During infusion of a nonvasodepressor dose of PGE2 AP
again rose significantly, due largely to an increase in GC, as did
R and RTA (Table 1). Mild declines in SNGFR and QA were
observed, although these changes were not statistically signifi-
cant. As seen with PG!2 infusion, PGE2 led to an impressive
reduction in K1. This tendency of renal vasoconstriction is
similar to that described for the rat by Malik and McGiff [32]
and Gerber and Nies [31], During combined infusion of PGE2
and saralasin, GFR and SNGFR rose proportionately. Saralasin
effectively antagonized the increases in RE and RTA induced by
PGE2 alone and also reversed the declines in K1 and QA. Thus,
saralasin also transformed the renal action of PGE, from
vasoconstrictor to vasodilator.
Augmentation of endogenous levels of All, or exogenous
infusion of this peptide hormone, leads to striking alterations in
the glomerular microcirculation, characterized by reductions in
QA and K1 and increases in AP and RTA [8, Il, 27, 28]. When
verapamil or manganese, known antagonists of calcium entry
into smooth muscle cells, are infused concomitantly with All,
the above described effects of All are largely abolished [ill.
This reversal of the changes in renal arteriolar resistances, as
well as in K1, suggests that the action of A!! on the glomerular
microcirculation involves the participation of contractile ele-
ments within the glomerulus as well as in the walls of the
periglomerular arterioles.
In evaluating the possible mechanisms involved in mediating
the observed changes in K1, it should be recalled that Kf is the
product of total glomerular capillary filtering surface area, S.
and capillary hydraulic conductivity, k, (that is, K1 = S k).
Reductions in Kf can therefore be brought about by declines in
S, k, or both. Selective alterations in k are not likely to be
revealed in in-vivo studies of glomerular function and, to date at
least, neither permselective nor ultrastructural alterations of the
glomerular wall in response to a variety of K1-lowering agents
have been found consistently [9, 33, 34]. On the other hand,
considerable evidence has been amassed to suggest that the Kr
lowering effect of All may be the consequence of reductions in
S, perhaps by virtue of the action of All to promote glomerular
contraction [35, 36]. In this regard, Osborne et al [37] localized
radiolabeled Al! predominantly in mesangial areas of glomeruli
by autoradiographiic methods, and others have shown that
glomeruli can contract spontaneously [38] as well as in response
to A!! [35, 36]. In addition, specific receptors for All have been
identified in isolated whole glomeruli [35, 391.
The mesangial cell is morphologically well suited to a role in
regulating capillary surface area by virtue of its rich content of
intracellular contractile filaments [4 1—43]. These filaments have
been shown to contain actin and myosin proteins [42, 43]. As
observed by Ausiello et al [10] and Mahieu et a! [40], All elicits
a brisk contractile response in these cells in culture. Of interest,
AVP also promotes vigorous contraction of these cultured
mesangial cells [101. Indeed, the contractile response to AVP
was evident at the concentration of 10_Ia M, whereas All was
effective at a tenfold higher concentration (10- M). Identical
threshold concentrations of AVP and All have been shown to
characterize the contractile response of extrarenal vascular
smooth muscle in the rat [44]. Based on the foregoing, it seems
reasonable to propose that All and AVP are potentially impor-
tant physiologic regulators of mesangial cell contraction, and
thereby, glomerular capillary filtering surface area and Kf (see
pathway 1 in Fig. 1). For AVP, the finding in the present study
that Kf remained below control levels in the presence of
saralasin adds further support for the view that the action of
AVP on K1 is independent of an intermediary role for Al!.
Although pathway 1 in Fig. I provides an attractive mecha-
nism to account for the decline in Kf in response to A!! or AVP
in vivo, this pathway seems unlikely to explain how PTH and
prostaglandins also reduce K1, in that PTH and prostaglandins
fail to trigger contraction of mesangial cells, at least in vitro
[10]. In considering alternate mechanisms to account for the
observed declines in K1 with these substances, as well as the
other vasoactive compounds listed in the upper left hand panel
of Fig. I, three other pathways seem worthy of consideration. If
pathway 2 in Fig. 1 were operative, involving a direct effect of
these substances on mesangial contraction in vivo (but not in
vitro), the decline in Kf regularly elicited by these substances
would not be expected to be antagonized by saralasin. Nor
would a mechanism acting via pathway 4 in Fig. I be expected
to be reversed by saralasin. Alternatively, the various sub-
stances identified in the upper left hand panel of Fig. I may
evoke reductions in K1 by virtue of their propensity to augment
intraglomerular synthesis of cAMP [13—15]. This mechanism
seems especially attractive for several reasons. As already
mentioned, it has been shown in this laboratory recently that
infusion of DBcAMP leads to a brisk decline in K1 [5]. This
nucleotide derivative is known to mimic the action of endoge-
nous cAMP in a number of tissues, either through a direct
action or through inhibition of cAMP phosphodiesterase [45]. In
addition, mammalian glomeruli are rich in adenylate cyclase
[14] and isolated suspensions of glomeruli have been shown to
generate cAMP in response to prostaglandins, PTH, and hista-
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mine [13—15]. Moreover, because cAMP is a potent stimulus for
renal renin release [16—19], the possibility exists that these
vasoactive substances modulate Kf by virtue of their ability to
promote local intrarenal All formation, with the latter serving
as a direct mediator of mesangial cell contraction and the
resulting decline in Kf, as depicted in pathway 3 of Fig. I.
To evaluate this possibility, we infused saralasin concomi-
tantly with the various vasoactive substances tested in the
present study. As already noted, saralasin was extremely
effective in reversing the decline of K induced by DBcAMP,
PTH, PGI2, and PGE2, suggesting that the effects of these
substances on the glomerular microcirculation in general, and
K in particular, are critically dependent on an intermediary role
of A!!. As noted above, because histamine infusions also raise
renal and/or glomerular cAMP levels, All may also be involved
in their actions, a possibility that awaits further study. Thus, the
present findings suggest that the existence of two distinct
pathways for the humoral regulation of K (Fig. 4). One
pathway involves the direct stimulation of mesangial cell con-
traction, and All and lysine vasopressin, at least, appear to be
capable of attaching to specific receptor sites on these cells and
eliciting contractility [10, 47]. The other pathway also involves
akey role for All in initiating mesangial cell contraction, but the
intrarenal formation of All in this case seems to depend on
stimulation by cAMP. In view of the abundant recent evidence
demonstrating enhanced glomerular cAMP formation by PTH,
prostaglandins and a variety of other hormones [13—IS], and the
ability of cAMP to promote renal renin secretion and intrarenal
All formation [16—19], this pathway provides a very attractive
mechanism for explaining the observed fall in K with
DBcAMP, PTH, PG!2. and POE2.
The findings in the present study of parallel changes in QA
and K1 suggest that perfusion of the intimate circulation within
the mammalian glomerulus may be more variable and intermit-
tent than previously believed, In the frog, several investigators
have called attention to a continuously changing pattern of
vascular perfusion within single glomeruli in vivo [1—3]. Fur-
thermore, Elias et al [3] found that when glomerular blood flow
rates in the frog were low, only a few large glomerular channels
appeared patent, whereas when this flow rate became more
rapid, perfusion of numerous smaller vascular branches derived
from these larger pathways could be observed. Despite these
convincing visual demonstrations of the phenomenon of inter-
mittence of glomerular perfusion in the frog kidney studied in
vivo, Smith [4] opposed the likelihood of a similar process at
work in the mammalian kidney for reasons that we find far from
compelling. Nevertheless, because glomeruli on the surface of
the mammalian kidney are rarely accessible to direct study,
resolution of this question perforce awaited the development of
other approaches such as the one employed in the present
study. In our view, the findings in the present study clearly
suggest that perfusion and filtration within individual glomeruli
of the rat are subject to local variations and indicate that this
intermittency is influenced strongly by vasoactive humoral
substances, and especially by the renin-angiotensin system.
Additional studies are obviously required to evaluate the impor-
tance of this process to the overall regulation of glomerular
filtration in physiologic and pathologic states in mammals.
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